tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Genmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
RatingsGenmab’s Strong Market Position and Growth Potential Justify Buy Rating with $40 Price Target
3d ago
GMAB
Genmab reports net sales of Darzalex for Q3 2025 of $3.67B
PremiumThe Fly
Genmab reports net sales of Darzalex for Q3 2025 of $3.67B
4d ago
GMAB
Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
PremiumRatings
Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
8d ago
GMAB
Genmab price target raised to DKK 2,000 from DKK 1,900 at Deutsche Bank
PremiumThe Fly
Genmab price target raised to DKK 2,000 from DKK 1,900 at Deutsche Bank
12d ago
GMAB
Genmab price target raised to $49 from $46 at Truist
PremiumThe Fly
Genmab price target raised to $49 from $46 at Truist
12d ago
GMAB
MRUS
Genmab price target raised to $40 from $36 at H.C. Wainwright
PremiumThe FlyGenmab price target raised to $40 from $36 at H.C. Wainwright
16d ago
GMAB
Genmab’s Strategic Acquisitions and Promising Pipeline Drive Buy Rating
Premium
Ratings
Genmab’s Strategic Acquisitions and Promising Pipeline Drive Buy Rating
19d ago
GMAB
Genmab’s Strategic Acquisition of MRUS: A Long-Term Positive Move Enhancing Pipeline and Growth Potential
Premium
Ratings
Genmab’s Strategic Acquisition of MRUS: A Long-Term Positive Move Enhancing Pipeline and Growth Potential
19d ago
GMAB
Genmab price target raised to $34 from $32 at Leerink
PremiumThe Fly
Genmab price target raised to $34 from $32 at Leerink
19d ago
GMAB
MRUS
Video: Merus jumps after deal to be bought, MoonLake sinks after trial data
PremiumThe Fly
Video: Merus jumps after deal to be bought, MoonLake sinks after trial data
19d ago
ACB
CGC
Morning Movers: Tilray rises as Trump touts CBD benefits for seniors
PremiumThe Fly
Morning Movers: Tilray rises as Trump touts CBD benefits for seniors
19d ago
EA
NVO
Merus downgraded to Neutral from Buy at Citi
PremiumThe Fly
Merus downgraded to Neutral from Buy at Citi
19d ago
GMAB
MRUS
Genmab A/S’s Strategic Acquisition of Merus: A Compelling Buy Despite Short-term EPS Dilution
PremiumRatingsGenmab A/S’s Strategic Acquisition of Merus: A Compelling Buy Despite Short-term EPS Dilution
19d ago
GMAB
Genmab acquires Merus for $97 per share in cash or $8B
Premium
The Fly
Genmab acquires Merus for $97 per share in cash or $8B
19d ago
GMAB
MRUS
Genmab near deal to acquire Merus, Bloomberg says
Premium
The Fly
Genmab near deal to acquire Merus, Bloomberg says
20d ago
GMAB
MRUS
Genmab says Orbis holds 5.03% of share capital
PremiumThe Fly
Genmab says Orbis holds 5.03% of share capital
25d ago
GMAB
Genmab upgraded to Buy at Guggenheim on royalty revenue upside potential
PremiumThe Fly
Genmab upgraded to Buy at Guggenheim on royalty revenue upside potential
25d ago
ABBV
GMAB
Genmab upgraded to Buy from Neutral at Guggenheim
PremiumThe Fly
Genmab upgraded to Buy from Neutral at Guggenheim
25d ago
GMAB
Genmab price target raised to DKK 1,650 from DKK 1,500 at JPMorgan
PremiumThe Fly
Genmab price target raised to DKK 1,650 from DKK 1,500 at JPMorgan
1M ago
GMAB
Genmab price target raised to DKK 1,900 from DKK 1,750 at Deutsche Bank
PremiumThe FlyGenmab price target raised to DKK 1,900 from DKK 1,750 at Deutsche Bank
2M ago
GMAB
Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
Premium
The Fly
Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
2M ago
GMAB
Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity
Premium
Ratings
Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity
2M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >